This site is intended for healthcare professionals

Novavax Inc.,confirms European Medicines Agency review of COVID-19 vaccine, Nuvaxovid, filed for conditional marketing authorization.

Read time: 1 mins
Last updated:20th Nov 2021
Published:18th Nov 2021
Novavax, Inc, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that European Medicines Agency (EMA) has begun its evaluation of an application for conditional marketing authorization (CMA) for Novavax' COVID-19 vaccine, which will be marketed in the European Union under the brand name Nuvaxovid.

The company announced earlier this month that it had completed the submission of all data and modules required by EMA for regulatory evaluation of NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant. EMA has indicated that its assessment will proceed under an accelerated timeline, with an opinion issued potentially within weeks.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.